Background
Methods
Data source and search strategy
Study selection
Characteristics of participants
Characteristics of interventions
Characteristics of outcomes
Data extraction and quality assessment
Data synthesis and analysis
Subgroup and sensitivity analysis
Results
Description of studies
Study (Country) | Study Population a | Outpatient arm | Inpatient arm | Primary outcome |
---|---|---|---|---|
Beckmann, 2019 [10] (Australia) | ≥37 + 0 weeks’ gestation, Bishop score < 7, residing < 60 min from the hospital | Priming with balloon catheter (n = 215) | Priming with prostaglandin 2 mg gel or 10 mg controlled-release tape (n = 233) | Composite measure of neonatal outcomes comprising of one or more of: admission to a neonatal special or intensive care nursery, need for intubation, and/or external cardiac compressions at birth, neonatal academia at birth, hypoxic ischaemic encephalopathy, neonatal seizure, neonatal infection, persistent pulmonary hypertension of the newborn, stillbirth or neonatal death |
Kuper, 2018 [11] (USA) | Parous women ≥39 weeks’ gestation, cervical dilation ≤3 cm, or if 2-3 cm dilated less than 80% effacement, reassuring fetal heart rate monitoring | Priming with balloon catheter, with oxytocin initiated upon readmission (n = 65) | Priming with balloon catheter and concomitant oxytocin infusion (n = 64) | Duration of time from labour ward admission until delivery |
Policiano, 2016 [12] (Portugal) | ≥41 weeks’ gestation or with a medical indication for labour induction), Bishop score < 6 | Priming with balloon catheter (n = 65) | Priming with balloon catheter (n = 65) | Change of Bishop score between application and removal of balloon catheter |
Wilkinson 2015, [18] COPRA Trial (Australia) | 37–42 weeks’ gestation, Bishop score < 7 | Priming with balloon catheter (n = 33) | Priming with balloon catheter (n = 15) | Oxytocin use |
Women ≥18 years old, ≥37 weeks’ gestation, Bishop score < 7 and cervical dilation < 2 cm, no regular uterine contractions. | Priming with balloon catheter (n = 50) | Priming with vaginal prostaglandin E2 gel [2 mg for nulliparous and 1 mg for parous women] (n = 51) | Vaginal birth within 12 h of admission, inpatient hours between randomization and birth | |
Women ≥18 years of age, 37–42 weeks’ gestation, living within 40 min of hospital with transport and having a telephone. | Priming with prostaglandin E2 gel [2 mg for nulliparous and 1 mg for parous women] (n = 411) | Priming with prostaglandin E2 gel [2 mg for nulliparous and 1 mg for parous women] (n = 416) | Oxytocin use | |
Rijnders 2011 [21] (Netherlands) | Women ≥18 years of age, 41 + 5–42 weeks’ gestation, no neonatal infections in previous pregnancies, and negative GBS status. | Amniotomy (at home) followed by 12 h of expectant management (n = 270) | Referral to an obstetrician for monitoring and induction of labour according to local guidelines. (n = 251) | Spontaneous birth without intervention. |
Biem 2002 [20](Canada) | ≥ 37 weeks’ gestation, a reactive non-stress test, Bishop score ≤ 6, and reliable means of transportation to the hospital. | Priming with prostaglandin E2 10mg insert, and admitted 24 h after insertion (n = 150) | Priming with prostaglandin E2 10mg insert (n = 150) | Proportion in labour or delivered by 24 h, and maternal satisfaction. |
Sciscione 2001 [19] (USA) | ≥ 37 weeks’ gestation, Bishop score ≤ 5, access to a telephone, and living within 30 min from the hospital with reliable means of transportation. | Priming with balloon catheter followed by oxytocin infusion the next morning of cervical ripening until extrusion of catheter (n = 61) | Priming with balloon catheter, then oxytocin infusion was started once the catheter was extruded (n = 50) | Change in Bishop score from the initial assessment until reassessment the following morning for outpatients, or when the Foley was extruded for inpatients. |
Effect of interventions
Outcome | Studies | Outpatient events | Inpatient events | Estimate (95% CI) | I2 |
---|---|---|---|---|---|
Maternal morbidity and patient-reported outcomes | |||||
Chorioamnionitis during labour | 6 | 74/839 (8.82%) | 68/834 (8.15%) | RR 1.09 (0.80, 1.48) | 0 |
Maternal hyperstimulation | 5 | 12/858 (1.40%) | 17/865 (1.97%) | RR 0.72 (0.21, 2.41) | 35.80 |
Postpartum haemorrhage > 500 mL (vaginal births) | 4 | 132/709 (18.62%) | 123/715 (17.20%) | RR 1.10 (0.89, 1.37) | 0 |
Mean hospital anxiety-depression score | 2 | NA | NA | MD −0.045 points (− 0.32, 0.23) | 5.97 |
Fetal and neonatal outcomes | |||||
Neonatal Intensive Care Unit Admissions | 8 | 76/1269 (5.55%) | 82/1244 (6.59%) | RR 0.93 (0.69, 1.26) | 0 |
5-min Apgar score < 7 | 5 | 22/994 (2.21%) | 15/979 (1.53%) | RR 1.39 (0.73, 2.65) | 0 |
Meconium stained amniotic fluid | 4 | 129/724 (17.82%) | 123/728 (16.90%) | RR 1.06 (0.85, 1.32) | 0 |
Uterine hyperstimulation | 4 | 12/643 (1.87%) | 10/632 (1.58%) | RR 1.12 (0.47, 2.69) | 0 |
Perinatal mortality | 3 | 1/691 (0.14%)a | 0/714 (0%) | RR 1.65 (0.20, 13.32) | 0 |
Febrile morbidity or Antibiotic requirement | 3 | 29/518 (5.60%) | 31/499 (6.21%) | RR 0.82 (0.29, 2.30) | 25.02 |
Suspicious fetal heart tracing | 2 | 61/199 (30.65%) | 43/201 (21.39%) | RR 1.43 (1.10, 1.86) | 0 |
Hypoxic ischemic Encephalopathy | 2 | 3/626 (0.48%) | 3/649 (0.46%) | RR 1.02 (0.23, 4.48) | 0 |
Respiratory problems | 2 | 17/444 (3.83%) | 18/431 (4.18%) | RR 0.92 (0.48, 1.75) | 0 |
Labour outcomes | |||||
Caesarean delivery | 9 | 280/1319 (21.23%) | 279/1295 (21.54%) | RR 0.96 (0.77, 1.19) | 40.16 |
Spontaneous vaginal birth | 8 | 495/1258 (39.35%) | 484/1245 (38.88) | RR 1.02 (0.88, 1.19) | 67.58 |
Assisted vaginal birth | 8 | 231/1258 (18.36%) | 225/1245 (18.07%) | RR 1.03 (0.85, 1.25) | 12.93 |
Cervical priming time | 4 | NA | NA | MD 25.87 min (− 142.72, + 194.45) | 82.06 |
Participants entering labour or delivery within 24 h of induction | 4 | 221/643 (34.37%) | 230/632 (36.39%) | RR 0.93 (0.71, 1.22) | 56.59 |
Mean length of active labour (vaginal births) | 2 | NA | NA | MD 12.42 h (−29.51, 54.35) | 0 |
Resource-related outcomes | |||||
Need for oxytocin infusion | 6 | 615/1128 (54.52%) | 453/1116 (40.59%) | RR 1.31 (0.95, 1.82) | 93.12 |
Epidural use | 5 | 605/1078 (56.12%) | 395/1078 (36.66%) | RR 1.32 (0.84, 2.07) | 96.01 |
Total hospital admission time until delivery | 5 | NA | NA | MD − 171.50 min (− 475.98, + 132.97) | 90.93 |
Mean duration oxytocin infusion | 5 | NA | NA | MD 43.87 min (−64.76, + 150.50) | 82.58 |
Mean length of hospital stay | 4 | NA | NA | MD − 282.48 min (−404.73, −160.23) | 10.99 |
Total induction-to-delivery time | 4 | NA | NA | MD −107.98 min (− 332.73, + 116.78) | 67.06 |
Mean hospital cost per womanb | 2 | NA | NA | MD $144.83 (− 819.44, + 1109.10) | 37.52 |
Maternal morbidity and patient-reported outcomes
Perinatal outcomes
Labour outcomes
Resource-related outcomes
Subgroup analysis
Outcome | Studies | Outpatient events | Inpatient events | Estimate (95% CI) | I2 |
---|---|---|---|---|---|
Maternal and labour outcomes | |||||
Caesarean delivery | 4 | 27/224 (12.05%) | 41/194 (21.13%) | RR 0.56 (0.37, 0.85) | 0 |
Admission-to-delivery interval | 3 | NA | NA | MD − 370.86 min (− 722.54, − 19.19) | 41.50 |
Mean duration oxytocin infusion | 3 | N/A | N/A | 56.18 min (− 41.76, 154.11) | 0 |
Induction-to-delivery interval | 2 | NA | NA | −330.42 min (− 540.71, − 120.13) | 0 |
Neonatal outcomes | |||||
Neonatal intensive care unit admissions | 4 | 8/224 (3.57%) | 10/194 (5.15%) | RR 0.76 (0.30, 1.93) | 0 |
5-min Apgar score < 7 | 2 | 2/98 (2.04%) | 1/79 (1.27%) | RR 0.94 (0.11, 8.25) | 0 |
Meconium stained amniotic fluid | 2 | 12/98 (12.24%) | 12/79 (15.19%) | RR 0.81 (0.37, 1.78) | 0 |